Referral of Patients to Hepatology With Hepatoscope

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity Hospital, Antwerp

About this trial

Patients identified as being at risk of liver fibrosis because of a positive Fibrosis-4 (FIB-4) test in the primary care setting will be offered be enrolled in the trial and to undergo an Hepatoscope exam (external non-invasive ultrasound imaging exam) to screen for liver fibrosis (with stiffness measurements) and/or steatosis (with ultrasound parameters related to fatty liver). All patients presenting with a liver stiffness value of at least 6.5 kilopascal (kPa) will be referred to the tertiary hepatology consultations for further assessment. Hepatoscope measurements will be compared to the standard of care for these patients, as defined at the tertiary hepatology center.

Eligibility criteria

Qualifiers

Patients with any of the following

Elevated liver enzymes (AST, ALT, Gamma-GT, AP)

Type 2 diabetes

Elements of metabolic syndrome

Disqualifiers

Patients with active implants such as pacemakers, defibrillators, pumps, etc.

Patients presenting wounds at the location where the Hepatoscope probe shall be placed on patients' skin,

Pregnant and breastfeeding women,

People deprived of their freedom rights.

Trial design

Treatments tested in this trial

  • Hepatoscope

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators